Medical University Vienna Cardiovascular Tissue Regeneration and Repair (PhD Programme)
Medical University Vienna

Medical University Vienna

Cardiovascular Tissue Regeneration and Repair (PhD Programme)

Vienna, Austria

PhD

6 semesters

English

Full time

On-Campus

Key Summary

About: MedUni Vienna’s PhD in Cardiovascular Tissue Regeneration and Repair trains researchers in regenerative medicine for heart pathologies. It covers induced pluripotent stem cells, cardiac organoids, tissue engineering, 3D printing, and cell-free approaches like secretomes, extracellular vesicles (EVs), growth factors, non-coding RNAs, gene therapies and biomaterials. It studies endogenous repair stimulation (therapeutics, genetic and epigenetic modification, ischemic conditioning) and exogenous strategies (cells, tissues, ATMPs), and stresses translating preclinical advances to human therapies.

Career Outcomes: Academic researcher, postdoctoral fellow, translational scientist, biotech R&D scientist, tissue engineer, clinical research associate, regulatory affairs specialist, medical science liaison, entrepreneur in regenerative medicine, industry consultant

Regenerative medicine is considered a key technology of the present and future medicine, with potential new therapies for cardiovascular, skin, neurological, and many other diseases. The majority of the cardiovascular regeneration research focused on ischemic heart disease. Still, it should also encompass other cardiovascular disorders, such as oncologic treatment-induced cardiotoxicity, or congenital and metabolic heart diseases or brain-heart axis repair.

This study program focuses on cardiovascular tissue pathologies and aims to elaborate methods for tissue regeneration and repair in this context. In the last twenty years, some evolutionary breakthroughs in tissue regeneration have been achieved, including the development of induced pluripotent stem cells (ips), identification of essential characteristics of regenerative cell types, development of cardiac organoids, tissue engineering and 3d printing. Beyond cell-based cardiac repair technology, regenerative medicine also involves the application of cell-free materials such as secretomes of regenerative cells, extracellular vesicles (EVS), growth factors, non-coding RNAS and gene therapies, biomaterials and several types of engineered tissues.

Regenerative medicine can be divided into two complementary strategies:

  • stimulation of the endogenous repair mechanisms by applied therapeutics (eg. synthetic or biologically derived factors, genetic and epigenetic modifications) or interventions (eg. ischemic conditioning, cardioprotection), and
  • exogenous regeneration modes through use of cells, tissues, or other biotechnological products, such as advanced therapy medicinal products, ATMPs. In contrast to pre-clinical data, human cardiac regenerative therapies led to a moderate success in improvement of cardiac performance, reduction of infarct size, prevention of left ventricular remodelling and decreased mortality and cardiovascular morbidity. Therefore, it is fundamental to understand the underlying biological mechanisms and translate the therapeutic efficacy gained in pre-clinical experiments to human conditions.